Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to ...
Extraordinary General Meeting of Shareholders to Approve Business Combination Scheduled for May 27, 2026BOSTON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Factorial Inc. (“Factorial” or the ...
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement ...
Zacks Investment Research on MSN
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock?
Cartesian Therapeutics, Inc. (RNAC) shares ended the last trading session 10.3% higher at $7.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate ...
-- In cohort of three patients intended to test safety, all patients showed full-class improvement in the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification and substantial ...
In other recent news, Cartesian Therapeutics has been the focus of several updates from financial analysts. Cantor Fitzgerald reaffirmed its Overweight rating for the company, maintaining a price ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results